Article Dans Une Revue ACS Infectious Diseases Année : 2025

Reductive Activation of Artefenomel (OZ439) by Fe(II)-Heme, Related to Its Antimalarial Activity

Résumé

The 1,2,4-trioxolane antimalarial drug, OZ439 (artefenomel), exhibits cross-resistance to artemisinins in vitro with similar survival rates of artemisinin-resistant parasites after dihydroartemisinin or OZ439 exposure, suggesting that this drug shares some mechanisms of action with artemisinins. In this way, we investigated the in vitro reductive activation of OZ439 by heme in the presence of dithionite, demonstrating the formation of covalent heme-drug adducts. However, in the presence of the biologically abundant reductant glutathione instead of dithionite, heme-drug adducts were not detected, contrary to artemisinin that efficiently alkylates heme regardless of the reductant used. Conversely, the C-centered radical of OZ439 resulting from heme-mediated activation of the drug reacts with the thiol function of glutathione, thus confirming the ability of this drug to alkylate proteins or other biological targets. So, the difference in the mechanism of action between artemisinin and OZ439 in vivo may rely on the different proportions between heme alkylation and protein alkylation.

Fichier principal
Vignette du fichier
Nguyen, Reductive activation of artefenomel, 2025.pdf (948.5 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-04928043 , version 1 (05-02-2025)

Licence

Identifiants

Citer

Michel Nguyen, Lucie Paloque, Jeanne Manaranche, Mickaël Chabbert, Alexandre Hamouy, et al.. Reductive Activation of Artefenomel (OZ439) by Fe(II)-Heme, Related to Its Antimalarial Activity. ACS Infectious Diseases, 2025, 11 (1), pp.216-225. ⟨10.1021/acsinfecdis.4c00787⟩. ⟨hal-04928043⟩
799 Consultations
128 Téléchargements

Altmetric

Partager

  • More